DDInter255 DDInter1297
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Busulfan {u} (Compound) upregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Busulfan {u} (Compound) upregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Busulfan {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Busulfan {u} (Compound) upregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Busulfan {u} (Compound) upregulates {v} (Gene) HLA-DRA
HLA-DRA {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Busulfan {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Busulfan {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Niraparib
Busulfan {u} (Compound) downregulates {v} (Gene) PPARG
PPARG {u} (Gene) is bound by {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Busulfan (Compound) upregulates ABL1 (Gene) and ABL1 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Busulfan (Compound) upregulates ABL1 (Gene) and ABL1 (Gene) is bound by Nilotinib (Compound) and ABL1 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Busulfan (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Busulfan (Compound) upregulates ABL1 (Gene) and ABL1 (Gene) is downregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Busulfan (Compound) upregulates HLA-DRA (Gene) and HLA-DRA (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Busulfan (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Busulfan (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Niraparib
Busulfan (Compound) downregulates PPARG (Gene) and PPARG (Gene) is bound by Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib